SIGLEC9 and neoplasm: SIGLEC9 triggered a signal that led to the degradation of focal adhesion kinase (FAK), associated in a great manner with PI3K-Akt signaling, in tumor cells through an interaction between SIGLEC9 on immune cells and its coreceptors on tumor cells via sialylglycoconjugates, leading to modulation of tumor cell adhesion kinetics.